Progression of Electrocardiographic Abnormalities in Type 1 Diabetes During 16 Years of Follow‐up: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study by Soliman, Elsayed et al.
Himmelfarb Health Sciences Library, The George Washington University 
Health Sciences Research Commons 
GW Biostatistics Center George Washington University Biostatistics Center 
3-2016 
Progression of Electrocardiographic Abnormalities in Type 1 
Diabetes During 16 Years of Follow‐up: The Epidemiology of 
Diabetes Interventions and Complications (EDIC) Study 
Elsayed Soliman 
Jye-Yu Backlund 
Ionut Bebu 
George Washington University 
Yabing Li 
Zhu-Ming Zhang 
See next page for additional authors 
Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/biostatscenter_facpubs 
 Part of the Biostatistics Commons, and the Epidemiology Commons 
APA Citation 
Soliman, E., Backlund, J., Bebu, I., Li, Y., Zhang, Z., Cleary, P. A., & Lachin, J. M. (2016). Progression of 
Electrocardiographic Abnormalities in Type 1 Diabetes During 16 Years of Follow‐up: The Epidemiology of 
Diabetes Interventions and Complications (EDIC) Study. Journal of the American Heart Association, (). 
http://dx.doi.org/10.1161/JAHA.115.002882 
This Journal Article is brought to you for free and open access by the George Washington University Biostatistics 
Center at Health Sciences Research Commons. It has been accepted for inclusion in GW Biostatistics Center by an 
authorized administrator of Health Sciences Research Commons. For more information, please contact 
hsrc@gwu.edu. 
Authors 
Elsayed Soliman, Jye-Yu Backlund, Ionut Bebu, Yabing Li, Zhu-Ming Zhang, Patricia A. Cleary, and John M. 
Lachin 
This journal article is available at Health Sciences Research Commons: https://hsrc.himmelfarb.gwu.edu/
biostatscenter_facpubs/154 
Progression of Electrocardiographic Abnormalities in Type 1 Diabetes
During 16 Years of Follow-up: The Epidemiology of Diabetes
Interventions and Complications (EDIC) Study
Elsayed Z. Soliman, MD, MSc, MS, FAHA, FACC; Jye-Yu C. Backlund, MPH; Ionut Bebu, PhD; Yabing Li, MD; Zhu-Ming Zhang, MD, MPH;
Patricia A. Cleary, MS; John M. Lachin, ScD; for the DCCT/EDIC Research Group*
Background-—The electrocardiogram (ECG) is an objective tool for cardiovascular disease (CVD) risk assessment.
Methods and Results-—We evaluated distribution of ECG abnormalities and risk factors for developing new abnormalities in 1314
patients with type 1 diabetes (T1D) from the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Annual ECGs
were centrally read. ECG abnormalities were classified as major and minor according to the Minnesota ECG Classification. At EDIC
year 1 (baseline), 356 (27.1%) of the participants had at least 1 ECG abnormality (major or minor) whereas 26 (2%) had at least one
major abnormality. During 16 years of follow-up, 1016 (77.3%) participants developed at least 1 new ECG abnormality (major or
minor), whereas 172 (13.1%) developed at least 1 new major abnormality. Independent risk factors for developing new major ECG
abnormalities were: age, current smoking, increased systolic blood pressure, and higher glycosylated hemoglobin (hazard ratio [HR]
[95% CI]: 1.04 [1.02–1.06] per 1-year increase, 1.75 [1.22–2.53], 1.03 [1.01–1.05] per 1 mm Hg increase, and 1.16 [1.04–1.29]
per 10% increase, respectively). Independent risk factors for developing any new ECG abnormalities (major or minor) were age and
systolic blood pressure (HR [95% CI]: 1.02 [1.01–1.03] per 1-year increase and 1.01 [1.00–1.02] per 1 mm Hg increase,
respectively).
Conclusions-—New ECG abnormalities commonly occur in the course of T1D, consistent with the recognized increasing risk for
CVD as patients age. Advanced age, increased systolic blood pressure, smoking, and higher HbA1c are independent risk factor for
developing major ECG abnormalities, which underscores the importance of tight glucose control in T1D in addition to management
of common CVD risk factors. ( J Am Heart Assoc. 2016;5:e002882 doi: 10.1161/JAHA.115.002882)
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T he resting 12-lead electrocardiogram (ECG) is the mostaccessible test for screening and detection of cardio-
vascular disease (CVD).1 In addition to its role in assessment
of prevalent CVD, ECG abnormalities have also been used to
predict poor outcomes in different populations.2–13
Patients with type 1 diabetes (T1D) are at a higher risk of
CVD compared with age-matched individuals without dia-
betes.14–16 Understanding the determinants and risk factors
for developing new ECG abnormalities in T1D could facilitate
better understanding of CVD in this high-risk population and
identify those who may benefit from closer follow-up and
aggressive risk factor management. Currently, there are no
reports on the progression of ECG abnormalities in patients
with T1D.
Our objectives for this study were 3-fold. First, we sought
to examine the distribution of ECG abnormalities in patients
with T1D at the time of enrollment in the Epidemiology of
Diabetes Interventions and Complications (EDIC) study.
Second, we studied the progression of these abnormalities
during 16 years of follow-up. Third, we sought to identify
participants’ characteristics and CVD risk factors that are
associated with the occurrence of new major or any (major or
minor) new ECG abnormalities during EDIC.
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Methods
The EDIC study started in 1994 (year 1 of the study, baseline
herein) as an observational follow-up of the Diabetes Control
and Complications Trial (DCCT). The DCCT, previously
described in detail,17 was a controlled clinical trial comparing
the effects of intensive versus conventional diabetes therapy
on long-term diabetes complications, including retinopathy,
nephropathy, and neuropathy. During 1983–1989, 1441
individuals ages 13 to 39 years old were enrolled; 726
participants into the primary prevention cohort (diabetes
duration 1–5 years, no retinopathy, and urinary albumin
excretion rate [AER] <40 mg/day) and 715 into the sec-
ondary intervention cohort (1–15 years in duration, very mild-
to-moderate nonproliferative retinopathy, and AER ≤200 mg/
day). Intensive therapy (n=711) aimed to achieve levels of
glycemia as close to the nondiabetic range as safely possible,
whereas conventional therapy (n=730) aimed to maintain
clinical well-being with no specific glucose targets. At the end
of the DCCT (1993), participants in the conventional treat-
ment group were instructed in intensive diabetes therapy. In
1994, all surviving DCCT participants were invited to join the
EDIC observational study. The study was approved by each
study site’s institutional review board. All participants
provided written informed consent. For the purpose of this
analysis, we included the 1314 EDIC participants (93% of the
surviving the DCCT cohort) with ECGs at EDIC year 1 (1994)
visit and at least 1 ECG during follow-up. Figure 1 shows the
disposition of EDIC participants in this analysis.
Electrocardiography
EDIC participants had annual 12-lead resting ECG recording.
ECG tracings were centrally read at an ECG core facility;
initially (years 1–11) at the University of Minnesota ECG
Reading Center (Minneapolis, MN), then at the Epidemiolog-
ical Cardiology Research (EPICARE) Center of Wake Forest
School of Medicine (Winston-Salem, NC) (years 12–16). The
change in the ECG reading center after EDIC year 11 did not
affect the risk of a new abnormality (P value of interaction
between reading center and DCCT treatment group for any
abnormalities and major abnormalities were 0.98 and 0.65,
respectively).
ECG abnormalities from all visits were classified as major
and minor ECG abnormalities using the standard Minnesota
ECG Classification.18 Major ECG abnormalities included major
ventricular conduction defects (complete left or right bundle
branch block, major ventricular conduction delay with QRS
≥120 ms), definite myocardial infarction (defined as the
presence of major Q-wave abnormalities), possible myocardial
infarction (defined as the presence of minor Q/QS-wave plus
major ST/T abnormalities), isolated major ST/T-wave
abnormalities, left ventricular hypertrophy with strain pattern,
advanced atrioventricular (AV) conduction abnormalities (com-
plete or second-degree AV block), pacemaker, atrial fibrillation/
flutter, and others. Minor ECG abnormalities included minor
isolated Q/QS-wave abnormalities, minor isolated ST/T abnor-
malities, high R waves/increased QRS voltage denoting left or
right ventricular hypertrophy without strain pattern, nonis-
chemic ST segment elevation, incomplete (left or right) bundle
branch block, short PR interval, left-axis deviation, right-axis
deviation, atrial and ventricular premature beats, and others.
This analysis focuses on major ECG abnormalities (defined
as presence of at least 1 major ECG abnormality) and on any
ECG abnormalities (at least 1 major or minor ECG abnormal-
ity) during EDIC follow-up.
Covariates
Demographic variables (age and sex) were self-reported.
Hypertension was defined as systolic blood pressure
≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or use
of antihypertensive medications. Fasting lipid profile was
assessed biannually. Hyperlipidemia was defined as low-
density lipoprotein (LDL)-cholesterol level ≥130 mg/dL or use
of lipid-lowering agents. Weighted mean values of body mass
index, blood pressure, lipids, and glycosylated hemoglobin
DCCT / EDIC patients
N=1441
Completed DCCT
N=1422
Any ECG in EDIC 1-16
N=1400
Visit at EDIC year 1
N=1322
At least one follow up visit
during EDIC year 2-16
N=1314
11 deaths
8 didn’t come in at
DCCT close out
No visit at EDIC year 1
(including 3 deaths)
N=78
No follow up visit
during EDIC year 2-16
(including 1 death at
EDIC year 3)
N=8
▼
▼
▼
▼
▼
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Figure 1. Flow chart of inclusion and exclusion criteria. DCCT
indicates Diabetes Control and Complications Trial; EDIC, Epidemi-
ology of Diabetes Interventions and Complications (EDIC) Study.
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(HbA1c) over the combined DCCT and EDIC study duration
were computed with weights proportional to the time interval
between values owing to the differences in the intervals
between visits during DCCT and EDIC. Microalbuminuria was
defined as AER ≥30 mg/24 hours (at baseline or ever during
DCCT/EDIC).
Table 1. Participants Characteristics at Baseline, EDIC Study Year 1
All Participants
Major Abnormality Any Abnormality
Yes (N=26) No (N=1288) P Value* Yes (N=356) No (N=958) P Value*
Age, yr 35.17.0 36.17.8 35.17.0 0.46 34.77.1 35.26.9 0.30
Female (%) 47.5 53.9 47.4 0.51 41.6 49.7 0.009
Race (% white) 96.3 92.3 96.4 0.66 94.7 96.9 0.13
Intensive treatment group (%) 49.9 42.3 50.1 0.43 50.3 49.8 0.87
Primary cohort (%) 49.7 38.5 49.9 0.25 51.4 49.1 0.45
Duration of diabetes, yr 13.64.9 13.94.7 13.54.9 0.63 13.35.3 13.64.8 0.07
Current smoking (%) 19.2 23.1 19.1 0.61 16.6 20.2 0.14
Body mass index, kg/m2 26.14.0 26.44.5 26.14.0 0.91 25.73.7 26.34.1 0.030
Body mass index ≥30 kg/m2 (%) 13.7 15.4 13.7 0.80 11.5 14.5 0.16
Systolic blood pressure, mm Hg 11712 12317 11712 0.11 11813 11712 0.97
Diastolic blood pressure, mm Hg 759 748 759 0.51 759 759 0.18
HbA1c (%) 8.11.4 8.21.4 8.11.4 0.90 8.11.4 8.11.3 0.20
Weighted mean HbA1c (%) 8.11.3 8.41.5 8.11.3 0.41 8.11.4 8.21.3 0.29
HDL cholesterol, mg/dL 5414 5816 5414 0.18 5414 5414 0.63
Non-HDL cholesterol, mg/dL 13337 13127 13337 0.89 13037 13437 0.010
LDL cholesterol, mg/dL 11531 11322 11531 0.91 11332 11631 0.021
Total cholesterol, mg/dL 18736 19025 18736 0.43 18336 18836 0.008
Triglyceride, mg/dL 9175 10386 9075 0.86 8775 9275 0.07
Microalbuminuria (%) 16.0 19.2 15.9 0.65 15.2 16.3 0.62
EDIC indicates Epidemiology of Diabetes Interventions and Complications (EDIC) Study; HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*P value is based on chi-square test for categorical variables and Wilcoxon rank sum test for continuous variables.
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Figure 2. Cumulative incidence of ECG abnormalities during 16 years of EDIC follow-up.
ECG indicates electrocardiogram; EDIC, Epidemiology of Diabetes Interventions and
Complications (EDIC) Study.
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Statistical Analysis
Participants’ characteristics were compared using Wilcoxon
rank-sum tests for quantitative variables and chi-square tests
for categorical variables.19 The advantage of the Wilcoxon
over the t test in this situation is its greater power under
distributions other than the normal, and it has a power trivially
less than the t test when the distributions are normal. The
Kaplan–Meier method estimated the cumulative incidence of
the new ECG abnormalities (major abnormality and any
abnormality, separately).20
The EDIC baseline evaluation herein refers to the EDIC
year 1 visit, 1 year after the close of the DCCT randomized
treatment phase. Each risk factor was entered as a
baseline variable and as a time-varying covariate, sepa-
rately, in models initially adjusted for age and sex. Hazard
ratios (HRs) associated with baseline and time-varying
covariates were estimated using separate Cox proportional
hazards models21 aimed to examine the association
between baseline participants’ characteristics and CVD risk
factors with developing new ECG abnormalities (major
abnormality and any abnormality, separately) during EDIC
follow-up. In multivariate risk factor models, the most
significant risk factor for the multivariate association among
similar variables (eg, systolic or diastolic blood pressure)
was used in the final multivariable models to avoid
collinearity. The proportional hazards assumption was
tested by adding time-dependent interaction terms between
the covariates and log (time).20
All analyses were performed using SAS software (version
9.3; SAS Institute Inc., Cary, NC). P<0.05 was considered
significant.
Results
Table 1 shows the baseline (EDIC year 1) characteristics of
the 1314 patients with T1D included in these analyses who
were 35.17.0 years old, 47.3% female, and 96.3% white. At
baseline, 356 (27.1%) participants had at least 1 ECG
abnormality whereas 26 (2%) had at least 1 major ECG
abnormality. The most common minor ECG abnormalities at
baseline were short PR interval (n=96; 7.3%), and nonischemic
ST elevation (n=61; 4.6%). The most common major ECG
abnormalities at baseline were ECG evidence of definite or
possible myocardial infarction (n=13; 1%) and isolated major
ST/T abnormalities (n=10; 0.8%).
Those with and without baseline major ECG abnormalities
did not differ in any initial characteristics. On the other hand,
there were more men, and lower body mass index, non-high-
density lipoprotein (HDL)-cholesterol, LDL-cholesterol, and
total cholesterol levels among EDIC participants with any
abnormal ECGs versus no abnormality at the initial evaluation
(Table 1).
During 16 years of follow-up, 1016 (77.3%) participants
developed at least 1 new ECG abnormality (major or minor),
whereas 172 (13.1%) participants developed at least 1 new
major abnormality. Median time of the occurrence of these
abnormalities was EDIC year 8 (95% CI, 7–10 years). Figure 2
shows the cumulative incidence of any new ECG abnormal-
ities during follow-up. Rates of occurrence of new ECG
abnormalities did not differ by sex, study cohort, or previous
DCCT treatment assignment. On the other hand, patients age
40 years and older or with higher baseline HbA1c were more
likely to develop new major ECG abnormalities (Table 2).
The most common new minor ECG abnormalities that
occurred during follow-up were incomplete bundle branch
block (139; 10.6%) and minor isolated ST/T abnormalities
(n=131; 10.0%), whereas the most common new major ECG
abnormalities were isolated major ST/T abnormalities (n=69;
Table 2. Distribution of Occurrence of New ECG
Abnormalities During EDIC Follow-up by Baseline
Characteristics
Baseline Characteristics
New Major ECG
Abnormality, N (%)
Any New ECG
Abnormality, N (%)
All (n=1314) 172 (13.1) 1016 (77.3)
Age group, yr
<40 (n=931) 103 (11.1) 701 (75.3)
≥40 (n=383) 69 (18.0)* 315 (82.3)*
Gender
Female (n=624) 78 (12.5) 481 (77.1)
Male (n=690) 94 (13.6) 535 (77.5)
Study cohort†
Primary (n=653) 93 (14.2) 506 (77.5)
Secondary (n=661) 79 (12.0) 510 (77.2)
DCCT treatment group‡
Intensive (n=656) 83 (12.7) 499 (76.1)
Conventional (n=658) 89 (13.5) 517 (78.6)
HbA1c
<8.0% (n=670) 70 (10.5) 505 (75.4)
≥8.0% (n=644) 102 (15.8)* 511 (79.4)
DCCT indicates Diabetes Control and Complications Trial; EDIC, Epidemiology of
Diabetes Interventions and Complications study; HbA1c, glycosylated hemoglobin.
*Significant differences; P<0.05.
†
Primary prevention cohort includes DCCT participants with diabetes duration 1 to
5 years, no retinopathy, and urinary albumin excretion rate <40 mg/day. Secondary
intervention cohort includes DCCT participants 1 to 15 years duration, very mild-to-
moderate nonproliferative retinopathy, and albumin excretion rate <200 mg/day.
‡
Intensive therapy aimed to achieve levels of glycemia as close to the nondiabetic range
as safely possible, whereas conventional therapy aimed to maintain clinical well-being
with no specific glucose targets.
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Table 3. Demographic Adjusted Associations Between Participants Characteristics and Risk Factors at EDIC Baseline and as Time-
Dependent Covariates Over Time With the Occurrence of New ECG Abnormalities
Variable*
New ECG Major Abnormality Any New ECG Abnormality
HR (95% CI) P Value HR (95% CI) P Value
Baseline age, yr† 1.05 (1.02–1.07) <0.001 1.02 (1.01–1.03) <0.001
Sex (male vs female)† 1.06 (0.78–1.43) 0.72 1.09 (0.96–1.24) 0.19
Study cohort (secondary vs primary) 0.79 (0.58–1.06) 0.12 0.97 (0.85–1.10) 0.63
DCCT treatment group (conventional vs intensive) 1.12 (0.83–1.52) 0.45 1.09 (0.96–1.25) 0.18
Diabetes duration at baseline, yr 0.97 (0.94–1.01) 0.10 1.00 (0.98–1.01) 0.66
Smoking (current)
Baseline 1.55 (1.10–2.19) 0.012 0.98 (0.83–1.15) 0.77
Current (yes vs no)‡ 1.85 (1.29–2.66) 0.001 1.12 (0.94–1.34) 0.21
Body mass index, kg/m2§
Baseline 1.00 (0.97–1.04) 0.93 1.00 (0.98–1.01) 0.64
Weighted mean‡ 1.02 (0.97–1.06) 0.49 1.00 (0.98–1.02) 0.90
Systolic blood pressure, mm Hg
Baseline 1.00 (0.99–1.02) 0.48 1.00 (0.99–1.01) 0.17
Weighted mean‡ 1.03 (1.01–1.05) 0.002 1.01 (1.00–1.02) 0.041
Diastolic blood pressure, mm Hg
Baseline 1.01 (1.00–1.03) 0.15 1.00 (0.99–1.01) 0.63
Weighted mean‡ 1.05 (1.02–1.08) 0.003 1.01 (0.99–1.02) 0.37
HDL cholesterol, mg/dLk
Baseline 0.99 (0.88–1.11) 0.87 0.98 (0.93–1.03) 0.49
Weighted mean‡ 0.95 (0.82–1.09) 0.44 0.99 (0.94–1.06) 0.82
Non-HDL cholesterol, mg/dLk
Baseline 1.06 (1.02–1.10) 0.004 1.01 (0.99–1.03) 0.27
Weighted mean‡ 1.07 (1.01–1.13) 0.015 1.01 (0.99–1.04) 0.36
LDL cholesterol, mg/dLk
Baseline 1.06 (1.01–1.11) 0.030 1.01 (0.99–1.03) 0.46
Weighted mean‡ 1.07 (1.00–1.14) 0.044 1.01 (0.98–1.04) 0.56
Triglyceride, mg/dLk
Baseline 1.02 (1.00–1.03) 0.011 1.01 (0.99–1.01) 0.25
Weighted mean‡ 1.04 (1.01–1.07) 0.015 1.01 (0.99–1.03) 0.15
Microalbuminuria
Baseline 1.36 (0.93–2.00) 0.11 1.20 (1.01–1.44) 0.041
Ever (Yes vs No)‡ 1.50 (1.11, 2.04) 0.009 1.09 (0.96, 1.25) 0.19
HbA1c (%) (per 10% increase)
Baseline¶ 1.12 (1.03–1.23) 0.001 1.00 (0.96–1.04) 0.97
Weighted mean‡# 1.20 (1.08–1.33) 0.001 1.03 (0.98–1.08) 0.22
ECG indicates electrocardiogram; EDIC, Epidemiology of Diabetes Interventions and Complications (EDIC) Study; HbA1c, glycosylated hemoglobin; HR, hazard ratio; HDL, high-density
lipoprotein; LDL, low-density lipoprotein.
*Each model was adjusted for age and sex.
†
One model included age and sex only.
‡Time-dependent covariate.
§
Body mass index was the only covariate with a nominally significant departure from the proportional hazard assumption.
k
All models including lipids were fit using 10 mg/dL because of the very small coefficient.
¶The log HbA1c value was used so that the HR per c-fold change in risk are c1.23056 and c0.00791 where 1.23056 and 0.00791 are the estimated regression coefficient for major and any
abnormality, respectively; c value of 1.1 corresponds to a 10% increase in the HbA1c value.
#
The log HbA1c value was used so that the HR per c-fold change in risk are c1.90967 and c0.30155 where 1.90967 and 0.30155 are the estimated regression coefficient for major and any
abnormality, respectively; c value of 1.1 corresponds to a 10% increase in the HbA1c value.
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40.1%) and ECG evidence of definite or possible myocardial
infarction (n=62; 4.7%).
In demographic adjusted Cox proportional hazard models,
age (at baseline), current smoking (at baseline and as a time-
varying covariate), higher systolic and diastolic blood pressure
(as a time-varying covariates), higher LDL-cholesterol (at
baseline and as a time-varying covariate), higher non-HDL-
cholesterol (at baseline and as a time-varying covariate),
higher triglycerides (at baseline and as a time-varying
covariate), microalbuminuria (as a time-varying covariate),
and higher HbA1c (baseline and time-varying covariate) were
significantly associated with development of new major ECG
abnormalities during follow-up. On the other hand, only age
(at baseline), systolic blood pressure (as a time-varying
covariate), and microalbuminuria (as a time-varying covariate)
were associated with development of any new ECG abnor-
malities (Table 3).
In a multivariable model, age (at baseline) as well as
current smoking, higher systolic blood pressure and higher
levels of HbA1c (all as time-varying covariates) were signif-
icantly associated with increased risk of developing new
major ECG abnormalities. On the other hand, only age (at
baseline) and higher systolic blood pressure (as a time-varying
covariate) were associated with increased risk for developing
Table 4. Multivariable Adjusted Associations of Selected Risk Factors With Occurrence of New ECG Abnormalities
Variable*
New Major ECG Abnormality Any New ECG Abnormality
HR (95% CI) P Value HR (95% CI) P Value
Age, yr (EDIC year 1) 1.04 (1.02–1.06) 0.001 1.02 (1.01–1.03) <0.001
Sex (male vs female) 0.92 (0.67–1.26) 0.60 1.04 (0.90–1.19) 0.61
Current smoking† (yes vs no) 1.75 (1.22–2.53) 0.002 1.12 (0.93–1.33) 0.23
Weighted mean systolic blood pressure†, mm Hg 1.03 (1.01–1.05) 0.003 1.01 (1.00–1.02) 0.045
Weighted mean HbA1c†‡ (per 10% increase) 1.16 (1.04–1.29) 0.008 1.02 (0.98–1.07) 0.33
ECG indicates electrocardiogram; EDIC, Epidemiology of Diabetes Interventions and Complications (EDIC) Study; HbA1c, glycosylated hemoglobin; HR, hazard ratio; HDL, high-density
lipoprotein.
*In addition to age and sex, the most significant variables from each category in Table 3 (smoking, blood pressure, lipid, microalbuminuria, and HbA1c) were selected to be included in
building separate multivariate models. In the new major ECG abnormality model, the lipid variable (ie, non-HDL at EDIC year 1 or weighted mean preceding event/censoring) and
microalbuminuria (ever) were no longer significant and were deleted after adjusting for smoking and weighted mean systolic blood pressure. In the any new ECG abnormality model, no
other risk factors were nominally significant. The proportional hazard assumption was met for all variables in the models.
†Included in the models as time dependent covariate.
‡The log HbA1c value was used so that the hazard ratio per c-fold change in risk are c1.51197 and c0.23687 where 1.51197 and 0.23687 are the estimated regression coefficient for major
and any abnormality, respectively; a value of c that equals 1.1 corresponds to a 10% increase in the HbA1c value.
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Figure 3. Risk of new ECG abnormalities across different levels of age. The red line represents the log
hazard (Y axis) of ECG abnormalities associated with different levels of age at baseline. The yellow line
represents the 95% CI of the log hazard (Y axis) of ECG abnormalities associated with different levels of
age at baseline. ECG indicates electrocardiogram.
DOI: 10.1161/JAHA.115.002882 Journal of the American Heart Association 6
ECG Abnormalities in Type 1 Diabetes Soliman et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at George Washington University on March 29, 2016http://jaha.ahajournals.org/Downloaded from 
any new ECG abnormalities (Table 4). Using a model free
estimate, the log HR for developing new major ECG abnor-
malities was a strong linear function of age, weighted mean
systolic blood pressure, and log mean HbA1c, whereas
weaker associations were observed for developing any ECG
abnormalities (Figures 3 through 5).
Discussion
In this analysis from the EDIC study, we examined
prevalence and progression of ECG abnormalities in
patients with T1D during 16 years of follow-up and looked
for factors associated with developing new abnormalities.
There are 2 key findings from our study. First, developing
new ECG abnormalities is common in the course of T1D; by
16 years of follow-up, 77.3% of the EDIC participants
developed at least 1 new ECG abnormality (major or minor),
with 13.1% developing at least 1 new major ECG abnor-
mality. Second, independent risk factors for developing new
major ECG abnormalities are advancing age, increased
systolic blood pressure, smoking, and higher HbA1c. On the
hand, independent risk factors for any new ECG abnormal-
ities are age and higher systolic blood pressure.
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Figure 4. Risk of new ECG abnormalities across different levels of weighted mean systolic blood
pressure. The red line represents the log hazard (Y axis) of ECG abnormalities associated with different
levels of weighted mean systolic blood pressure (Y axis). The yellow line represents the 95% CI of the log
hazard (Y axis) of ECG abnormalities associated with different levels of weighted mean systolic blood
pressure (Y axis). ECG indicates electrocardiogram.
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Figure 5. Risk of new ECG abnormalites across diffetent lelvels of weighted mean HbA1c. The red
line represents the log hazard (Y axis) of ECG abnormalities associated with different levels of log
weighted mean HbA1c (Y axis). The yellow line represents the 95% CI of the log hazard (Y axis) of ECG
abnormalities associated with different levels of log weighted mean HbA1c (Y axis). ECG indicates
electrocardiogram; HbA1c, glycosylated hemoglobin.
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Our findings could influence care of patients with T1D in a
number of ways. The increased incidence of ECG abnormal-
ities during the course of T1D suggests a potential use for
ECG to monitor progression of CVD in T1D. Also, identifying
factors associated with developing these abnormalities could
provide targets for prevention of CVD.
Several reports from different populations have shown
that ECG abnormalities reflect increased risk of CVD.2–13
Thus, our finding of higher occurrence of new ECG
abnormalities in patients with T1D highlights the increased
risk of CVD in this population as they age. Notably, the
reported prevalence of ECG abnormalities in the general
population using the same ECG classification system range
from 16% to 32%,22–26 which is lower than rates observed
in our study population of T1D. This is in accord with
previous reports showing that T1D is associated with higher
risk of CVD compared with age matched nondiabetic
populations.14–16
In the present report, in addition to common cardiovascu-
lar risk factors (advancing age, smoking, and higher systolic
blood pressure), higher HbA1c level was associated with an
increased risk of developing new major ECG abnormalities.
This finding underscores the importance of tight glucose
control in T1D. This is consistent with our past demonstration
of the salutary effects of intensive diabetes therapy compared
with conventional therapy on the risk of CVD in patients with
T1D.27 We have also previously demonstrated that intensive
diabetes therapy reduces the progression of atherosclerosis,
as measured by carotid intima-media thickness28 and coro-
nary artery calcification,29 which could have an impact on
development of ECG abnormalities.
The association between glycemia and CVD is well
established. Hyperglycemia, even below the ranges that
define diabetes, has been associated with increased risk of
CVD.30 Furthermore, hyperglycemia has been shown to be a
risk factor for microvascular complications, some of which
(eg, diabetic nephropathy) are risk factors for CVD.31–33 These
reports linking hyperglycemia to CVD provide some explana-
tion to our finding of the link between hyperglycemia and
developing new abnormalities in the ECG, the objective tool to
assess cardiovascular health. It is unknown, however, whether
interventions aimed at reducing glycemia will reverse ECG
abnormalities.
Our finding that increased systolic blood pressure and
smoking are independent risk factors for developing new
major ECG abnormalities is in line with the known risk of
CVD associated with these factors. Whether normalization
of ECG abnormalities could be used as a tool to monitor
successful management of these risk factors require further
investigation.
Advancing age and higher systolic blood pressure were the
only independent risk factors shared by both major and any
ECG abnormalities. However, despite not reaching statistical
significance, the direction of associations of the other risk
factors for developing new major abnormalities (higher HbA1c
and smoking) was similar to that noted for developing any
new ECG abnormalities. Attenuation of the effect of risk
factors in case of any new abnormality is likely because of the
minor abnormalities (the majority of any new ECG abnormal-
ity) being a milder form of CVD.
Our results have limitations. The majority of EDIC
participants are Caucasian, which may limit the
generalizability of our results to other races/ethnicities.
However, the ethnic makeup of the DCCT/EDIC cohort is
not substantially dissimilar from the general T1D population
that is largely Caucasians. We used global classification of
ECG abnormalities (major and any) rather than using
individual ECG abnormalities. Arguably, different individual
ECG abnormalities might have different risk factors. How-
ever, our approach of using global classification ECG
abnormalities is common, and several previous reports
have shown its usefulness for both assessment and
prediction of CVD.2–13 The main reason for us and for
previous reports for using global classification of ECG
abnormalities is the lack of enough power to use ECG
abnormalities individually in such type of analyses.
Despite these limitations, this is the first report on the
progression of ECG abnormalities in T1D. The uniform
collection of data, including centrally read ECG data, and
the long term follow-up with extensive phenotyping are just a
few of the many strengths of the EDIC study.
In conclusion, occurrence of new ECG abnormalities is
common in the course of T1D consistent with the
increasing risk for CVD with age. Independent risk factors
for developing new major ECG abnormalities are older age,
increased systolic blood pressure, smoking, and higher
HbA1c. On the other hand, independent risk factors for any
new ECG abnormalities are age and higher systolic blood
pressure. Further examination is needed to determine
whether interventions aimed at reducing glycemia will
reverse ECG abnormalities.
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